Oncolytics Biotech (ONCY) Net Cash Flow (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Net Cash Flow data on file, last reported at -$6.0 million in Q4 2025.

• On a quarterly basis, Net Cash Flow fell 85.57% year-over-year to -$6.0 million in Q4 2025; TTM through Dec 2025 was -$8.3 million, a 44.73% increase from a year earlier, with the FY2025 full-year figure at -$6.0 million, up 60.08% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$6.0 million, down from -$1.8 million in the prior quarter.
• Over the last five years, Net Cash Flow for ONCY reached as high as $16.4 million in Q3 2023 and fell as low as -$15.0 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$1.1 million across 5 years, with a median of -$2.8 million in 2021.
• Across the five-year window, Net Cash Flow plunged 654.63% in 2022 and soared 793.21% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at -$5.1 million in 2021, then tumbled by 193.39% to -$15.0 million in 2022, then soared by 78.58% to -$3.2 million in 2023, then dropped by 0.3% to -$3.2 million in 2024, then sank by 85.57% to -$6.0 million in 2025.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$6.0 million in Q4 2025, -$1.8 million in Q3 2025, and -$70727.8 in Q2 2025.